Русские видео

Сейчас в тренде

Иностранные видео


Скачать с ютуб Mastering hERG: Med Chem Strategies for Mitigating Cardiotoxicity Risks в хорошем качестве

Mastering hERG: Med Chem Strategies for Mitigating Cardiotoxicity Risks 6 месяцев назад


Если кнопки скачивания не загрузились НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если возникают проблемы со скачиванием, пожалуйста напишите в поддержку по адресу внизу страницы.
Спасибо за использование сервиса ClipSaver.ru



Mastering hERG: Med Chem Strategies for Mitigating Cardiotoxicity Risks

In the pursuit of safer drugs medicinal chemists often face the challenge of mitigating cardiotoxicity liabilities that are linked to hERG (human Ether-à-go-go-Related Gene) ion channel inhibition. In this Coffee Chat our team discusses some of the strategies and tactics medicinal chemists use to minimize hERG-related risks during lead optimization. They explore innovative design principles for reducing hERG affinity while maintaining on-target potency and share case studies of successful implementations. This session provides valuable insights and practical approaches to addressing hERG liabilities in your programs. Attendees submitted questions in advance and engaged with our team in a live Q&A session. Don't miss this opportunity to learn from industry case studies that successfully mitigated hERG liabilities. Drug Hunter Speakers: Dennis Hu Ph.D., CEO Dennis Koester Ph. D., Director, Industry Research and Relations Matt Hesse Ph.D., Sr. Scientific Editor 00:00 Introduction 00:30 hERG Fundamentals, Dennis Hu 09:18 Classic Strategies for hERG, Matt Hesse 15:51 Case Studies, Dennis Koester 25:33 Q&A For additional reading take a look at these Drug Hunter Premium articles: Ziritaxestat: https://drughunters.com/ziritaxestat The Galapagos team tackled a hERG issue on an ATX inhibitor program by switching from a piperidine to a piperazine significantly lowering the pKa. JNT-517: https://drughunters.com/JNT-517 Jnana mitigated a hERG liability on an amino acid transporter program by replacing a pyridazine with a urea significantly reducing lipophilicity. TNG348: https://drughunters.com/TNG348 In their USP1 program, the team at Tango Therapeutics addressed a hERG liability by reducing lipophilicity and lowering the pKa. Linvencorvir: https://drughunters.com/linvencorvir To address hERG liability with this capsid assembly modulator, the Roche team employed a zwitterion strategy by introducing a carboxylic acid. They mindfully incorporated steric hindrance around the carboxylic acid to minimize the formation of acyl glucuronides. Don't miss out on future sessions of this new interactive series! Register here: https://drughunter.com/coffee-chat-re... Presented as part of the Drug Hunter Coffee Chat series on August 15, 2024 Sign up for our free newsletter here: https://drughunter.com/newsletter-sig...

Comments